Haisco Pharmaceutical Group Co Ltd
002653
Company Profile
Business description
Haisco Pharmaceutical Group Co Ltd is a pharmaceutical company based in China. It is mainly engaged in the research, development, manufacture, and sale of drugs for liver disease. Its product portfolio includes parenteral nutrition drugs, antibiotics, anesthetic agents, digestive system drugs and tumour adjuvant drug series. The company's products are being used in first rank hospitals in China.
Contact
No. 17, Sanxiang Avenue
Shannan District
Tibet Autonomous Region
Zetang856000
CHNT: +86 8937834865
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
5,337
Stocks News & Analysis
stocks
Ask the analyst: How reliant are Guzman shares on international growth?
A year on from Guzman’s IPO, I catch up with Johannes Faul to explore what is baked into GYG’s valuation.
stocks
Nvidia: Back in business in China; Raising fair value estimate
Nvidia is poised to become more dominant than ever as it is allowed to sell its key H20 GPUs in China.
stocks
Our top ASX picks in every sector
These companies are our top choices for investors wanting to boost Aussie exposure.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,812.10 | 63.20 | -0.71% |
| CAC 40 | 7,766.21 | 41.96 | -0.54% |
| DAX 40 | 24,060.29 | 100.35 | -0.42% |
| Dow JONES (US) | 44,023.29 | 436.36 | -0.98% |
| FTSE 100 | 8,938.32 | 59.74 | -0.66% |
| HKSE | 24,753.60 | 163.48 | 0.66% |
| NASDAQ | 20,677.80 | 37.47 | 0.18% |
| Nikkei 225 | 39,635.09 | 42.93 | -0.11% |
| NZX 50 Index | 12,754.20 | 64.57 | 0.51% |
| S&P 500 | 6,243.76 | 24.80 | -0.40% |
| S&P/ASX 200 | 8,562.40 | 67.90 | -0.79% |
| SSE Composite Index | 3,501.63 | 3.37 | -0.10% |